Reported Earnings • May 16
Full year 2026 earnings released: EPS: ₹1.13 (vs ₹0.42 loss in FY 2025) Full year 2026 results: EPS: ₹1.13 (up from ₹0.42 loss in FY 2025). Revenue: ₹22.7b (up 9.2% from FY 2025). Net income: ₹287.4m (up ₹393.4m from FY 2025). Profit margin: 1.3% (up from net loss in FY 2025). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 35% per year but the company’s share price has only fallen by 14% per year, which means it has not declined as severely as earnings. Valuation Update With 7 Day Price Move • May 06
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to ₹58.58, the stock trades at a trailing P/E ratio of 36.8x. Average trailing P/E is 23x in the Chemicals industry in India. Total loss to shareholders of 29% over the past three years. Announcement • Apr 20
Meghmani Organics Limited to Report Q4, 2026 Final Results on May 09, 2026 Meghmani Organics Limited announced that they will report Q4, 2026 final results at 9:08 AM, Indian Standard Time on May 09, 2026 Valuation Update With 7 Day Price Move • Apr 06
Investor sentiment improves as stock rises 27% After last week's 27% share price gain to ₹46.50, the stock trades at a trailing P/E ratio of 29.2x. Average trailing P/E is 20x in the Chemicals industry in India. Total loss to shareholders of 47% over the past three years. New Risk • Mar 30
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: ₹9.34b (US$98.7m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (1.3x net interest cover). Earnings have declined by 52% per year over the past 5 years. Minor Risk Market cap is less than US$100m (₹9.34b market cap, or US$98.7m). Reported Earnings • Feb 01
Third quarter 2026 earnings released: ₹0.14 loss per share (vs ₹0.17 loss in 3Q 2025) Third quarter 2026 results: ₹0.14 loss per share (improved from ₹0.17 loss in 3Q 2025). Revenue: ₹5.09b (down 11% from 3Q 2025). Net loss: ₹35.3m (loss narrowed 20% from 3Q 2025). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 57 percentage points per year, which is a significant difference in performance. Announcement • Jan 19
Meghmani Organics Limited to Report Q3, 2026 Results on Jan 31, 2026 Meghmani Organics Limited announced that they will report Q3, 2026 results at 9:08 AM, Indian Standard Time on Jan 31, 2026 Reported Earnings • Nov 09
Second quarter 2026 earnings released: EPS: ₹0.45 (vs ₹0.36 loss in 2Q 2025) Second quarter 2026 results: EPS: ₹0.45 (up from ₹0.36 loss in 2Q 2025). Revenue: ₹6.05b (up 11% from 2Q 2025). Net income: ₹115.5m (up ₹208.2m from 2Q 2025). Profit margin: 1.9% (up from net loss in 2Q 2025). The move to profitability was driven by higher revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 84 percentage points per year, which is a significant difference in performance. Announcement • Oct 31
Meghmani Organics Limited to Report Q2, 2026 Results on Nov 08, 2025 Meghmani Organics Limited announced that they will report Q2, 2026 results at 12:08 PM, Indian Standard Time on Nov 08, 2025 Reported Earnings • Jul 31
First quarter 2026 earnings released: EPS: ₹0.50 (vs ₹0.66 loss in 1Q 2025) First quarter 2026 results: EPS: ₹0.50 (up from ₹0.66 loss in 1Q 2025). Revenue: ₹6.30b (up 52% from 1Q 2025). Net income: ₹126.8m (up ₹294.4m from 1Q 2025). Profit margin: 2.0% (up from net loss in 1Q 2025). The move to profitability was driven by higher revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 101 percentage points per year, which is a significant difference in performance. Announcement • Jul 22
Meghmani Organics Limited to Report Q1, 2026 Results on Jul 30, 2025 Meghmani Organics Limited announced that they will report Q1, 2026 results on Jul 30, 2025 Announcement • Jun 02
Meghmani Organics Limited, Annual General Meeting, Jun 28, 2025 Meghmani Organics Limited, Annual General Meeting, Jun 28, 2025, at 12:00 Indian Standard Time. Reported Earnings • May 12
Full year 2025 earnings released: ₹0.42 loss per share (vs ₹4.17 loss in FY 2024) Full year 2025 results: ₹0.42 loss per share (improved from ₹4.17 loss in FY 2024). Revenue: ₹21.2b (up 36% from FY 2024). Net loss: ₹106.0m (loss narrowed 90% from FY 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 93 percentage points per year, which is a significant difference in performance. Announcement • May 01
Meghmani Organics Limited to Report Q4, 2025 Results on May 10, 2025 Meghmani Organics Limited announced that they will report Q4, 2025 results at 9:08 AM, Indian Standard Time on May 10, 2025 Reported Earnings • Feb 09
Third quarter 2025 earnings released: ₹0.17 loss per share (vs ₹1.50 loss in 3Q 2024) Third quarter 2025 results: ₹0.17 loss per share (improved from ₹1.50 loss in 3Q 2024). Revenue: ₹5.69b (up 62% from 3Q 2024). Net loss: ₹43.9m (loss narrowed 89% from 3Q 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 90 percentage points per year, which is a significant difference in performance. Announcement • Jan 28
Meghmani Organics Limited to Report Q3, 2025 Results on Feb 08, 2025 Meghmani Organics Limited announced that they will report Q3, 2025 results at 12:08 PM, Indian Standard Time on Feb 08, 2025 Reported Earnings • Oct 27
Second quarter 2025 earnings released: ₹0.36 loss per share (vs ₹0.60 loss in 2Q 2024) Second quarter 2025 results: ₹0.36 loss per share (improved from ₹0.60 loss in 2Q 2024). Revenue: ₹5.56b (up 47% from 2Q 2024). Net loss: ₹92.7m (loss narrowed 40% from 2Q 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 82 percentage points per year, which is a significant difference in performance. Announcement • Oct 09
Meghmani Organics Limited to Report First Half, 2025 Results on Oct 26, 2024 Meghmani Organics Limited announced that they will report first half, 2025 results on Oct 26, 2024 Reported Earnings • Jul 28
First quarter 2025 earnings released: ₹0.66 loss per share (vs ₹1.36 loss in 1Q 2024) First quarter 2025 results: ₹0.66 loss per share (improved from ₹1.36 loss in 1Q 2024). Revenue: ₹4.23b (flat on 1Q 2024). Net loss: ₹167.6m (loss narrowed 51% from 1Q 2024). Announcement • Jul 17
Meghmani Organics Limited to Report Q1, 2025 Results on Jul 27, 2024 Meghmani Organics Limited announced that they will report Q1, 2025 results at 12:08 PM, Indian Standard Time on Jul 27, 2024 Reported Earnings • Jun 19
Full year 2024 earnings released: ₹4.17 loss per share (vs ₹9.35 profit in FY 2023) Full year 2024 results: ₹4.17 loss per share (down from ₹9.35 profit in FY 2023). Revenue: ₹15.7b (down 39% from FY 2023). Net loss: ₹1.06b (down 145% from profit in FY 2023). Announcement • Jun 13
Meghmani Organics Limited, Annual General Meeting, Jul 09, 2024 Meghmani Organics Limited, Annual General Meeting, Jul 09, 2024, at 12:00 Indian Standard Time. New Risk • May 22
New minor risk - Financial position The company has a high level of debt. Net debt to equity ratio: 52% This is considered a minor risk. Having a high level of debt increases the company's balance sheet risk. The company has a higher interest repayment burden, leading to the need to allocate a greater amount of its earnings towards servicing the debt, potentially limiting growth options or shareholder distributions. It can also increase the risk of bankruptcy if business conditions deteriorate enough that the company can no longer meet its debt obligations. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 19% per year over the past 5 years. Minor Risks High level of debt (52% net debt to equity). Paying a dividend despite having no free cash flows. Reported Earnings • May 12
Full year 2024 earnings released: ₹4.17 loss per share (vs ₹9.35 profit in FY 2023) Full year 2024 results: ₹4.17 loss per share (down from ₹9.35 profit in FY 2023). Revenue: ₹16.0b (down 37% from FY 2023). Net loss: ₹1.06b (down 145% from profit in FY 2023). Announcement • Apr 23
Meghmani Organics Limited to Report Q4, 2024 Results on May 11, 2024 Meghmani Organics Limited announced that they will report Q4, 2024 results at 12:08 PM, Indian Standard Time on May 11, 2024 Reported Earnings • Jan 31
Third quarter 2024 earnings released: ₹1.50 loss per share (vs ₹0.33 profit in 3Q 2023) Third quarter 2024 results: ₹1.50 loss per share (down from ₹0.33 profit in 3Q 2023). Revenue: ₹3.52b (down 36% from 3Q 2023). Net loss: ₹382.3m (down ₹465.8m from profit in 3Q 2023). Reported Earnings • Jan 31
Third quarter 2024 earnings released: ₹1.50 loss per share (vs ₹0.33 profit in 3Q 2023) Third quarter 2024 results: ₹1.50 loss per share (down from ₹0.33 profit in 3Q 2023). Revenue: ₹3.52b (down 36% from 3Q 2023). Net loss: ₹382.3m (down ₹465.8m from profit in 3Q 2023). Announcement • Jan 16
Meghmani Organics Limited to Report Q3, 2024 Results on Jan 30, 2024 Meghmani Organics Limited announced that they will report Q3, 2024 results on Jan 30, 2024 New Risk • Nov 10
New major risk - Financial position The company's interest payments are not well covered by earnings. Net interest cover: 0.9x This is considered a major risk. If the company is unable to fund interest repayments on its debt through profits, it may be forced into reducing its debt burden through selling assets, undertaking a potentially costly capital raising or even into bankruptcy in the worst case scenario. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (0.9x net interest cover). Earnings have declined by 11% per year over the past 5 years. Minor Risks Paying a dividend despite having no free cash flows. Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (0.7% net profit margin). Reported Earnings • Nov 09
Second quarter 2024 earnings released: ₹0.60 loss per share (vs ₹2.60 profit in 2Q 2023) Second quarter 2024 results: ₹0.60 loss per share (down from ₹2.60 profit in 2Q 2023). Revenue: ₹3.91b (down 40% from 2Q 2023). Net loss: ₹153.4m (down 123% from profit in 2Q 2023). Announcement • Nov 08
Meghmani Organics Limited Accepts the Resignation of Shalin Mehta as an Independent Director The board of directors of Meghmani Organics Limited in their meeting held on November 7, 2023, accepted the resignation tendered by Mr. Shalin Mehta as an Independent Director effective from close of business hours on November 7, 2023, due to pre-occupation and other personal commitments. Announcement • Oct 17
Meghmani Organics Limited to Report Q2, 2024 Results on Nov 07, 2023 Meghmani Organics Limited announced that they will report Q2, 2024 results on Nov 07, 2023 New Risk • Aug 16
New major risk - Revenue and earnings growth Earnings have declined by 5.0% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 5.0% per year over the past 5 years. Minor Risks High level of debt (46% net debt to equity). Paying a dividend despite having no free cash flows. Profit margins are more than 30% lower than last year (4.3% net profit margin). Reported Earnings • Aug 15
First quarter 2024 earnings released: ₹1.36 loss per share (vs ₹4.29 profit in 1Q 2023) First quarter 2024 results: ₹1.36 loss per share (down from ₹4.29 profit in 1Q 2023). Revenue: ₹4.33b (down 45% from 1Q 2023). Net loss: ₹345.0m (down 132% from profit in 1Q 2023). Announcement • Aug 03
Meghmani Organics Limited to Report Q1, 2024 Results on Aug 14, 2023 Meghmani Organics Limited announced that they will report Q1, 2024 results on Aug 14, 2023 Announcement • Jun 30
Meghmani Organics Limited Approves Final Dividend for the Financial Year 2022-23 Meghmani Organics Limited at its June 26, 2023 approved approved final dividend of INR 1.40 per share of INR 1 each for the financial year 2022-23. Upcoming Dividend • Jun 13
Upcoming dividend of ₹1.40 per share at 1.6% yield Eligible shareholders must have bought the stock before 20 June 2023. Payment date: 27 July 2023. Payout ratio is a comfortable 15% but the company is not cash flow positive. Trailing yield: 1.6%. Within top quartile of Indian dividend payers (1.5%). Higher than average of industry peers (0.9%). Reported Earnings • Jun 07
Full year 2023 earnings released: EPS: ₹9.35 (vs ₹11.97 in FY 2022) Full year 2023 results: EPS: ₹9.35 (down from ₹11.97 in FY 2022). Revenue: ₹25.5b (up 2.2% from FY 2022). Net income: ₹2.38b (down 22% from FY 2022). Profit margin: 9.3% (down from 12% in FY 2022). The decrease in margin was driven by higher expenses. Recent Insider Transactions • Jun 03
Executive Director recently bought ₹4.1m worth of stock On the 30th of May, Rameshbhai Patel bought around 50k shares on-market at roughly ₹82.04 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought ₹32m more in shares than they have sold in the last 12 months. Reported Earnings • Apr 30
Full year 2023 earnings released: EPS: ₹9.35 (vs ₹11.97 in FY 2022) Full year 2023 results: EPS: ₹9.35 (down from ₹11.97 in FY 2022). Revenue: ₹26.5b (up 6.0% from FY 2022). Net income: ₹2.38b (down 22% from FY 2022). Profit margin: 9.0% (down from 12% in FY 2022). The decrease in margin was driven by higher expenses. Valuation Update With 7 Day Price Move • Apr 05
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to ₹90.65, the stock trades at a trailing P/E ratio of 8.1x. Average trailing P/E is 19x in the Chemicals industry in India. Total loss to shareholders of 16% over the past year. Recent Insider Transactions • Feb 15
Executive Director recently bought ₹7.7m worth of stock On the 13th of February, Rameshbhai Patel bought around 78k shares on-market at roughly ₹98.73 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger purchase from another insider worth ₹13m. Insiders have collectively bought ₹42m more in shares than they have sold in the last 12 months. Recent Insider Transactions • Jan 27
MD & Director recently bought ₹13m worth of stock On the 25th of January, Natwarlal Patel bought around 131k shares on-market at roughly ₹98.67 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought ₹32m more in shares than they have sold in the last 12 months. Reported Earnings • Jan 23
Third quarter 2023 earnings released: EPS: ₹0.33 (vs ₹2.69 in 3Q 2022) Third quarter 2023 results: EPS: ₹0.33 (down from ₹2.69 in 3Q 2022). Revenue: ₹5.73b (down 10% from 3Q 2022). Net income: ₹83.5m (down 88% from 3Q 2022). Profit margin: 1.5% (down from 11% in 3Q 2022). The decrease in margin was driven by lower revenue. Announcement • Jan 12
Meghmani Organics Limited to Report Q3, 2023 Results on Jan 21, 2023 Meghmani Organics Limited announced that they will report Q3, 2023 results on Jan 21, 2023 Board Change • Nov 16
High number of new directors There are 5 new directors who have joined the board in the last 3 years. Non-Executive Independent Director Varesh Sinha was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Oct 23
Second quarter 2023 earnings released: EPS: ₹2.60 (vs ₹2.57 in 2Q 2022) Second quarter 2023 results: EPS: ₹2.60 (up from ₹2.57 in 2Q 2022). Revenue: ₹6.46b (up 18% from 2Q 2022). Net income: ₹661.5m (up 1.4% from 2Q 2022). Profit margin: 10% (down from 12% in 2Q 2022). The decrease in margin was driven by higher expenses. Reported Earnings • Jul 23
First quarter 2023 earnings released: EPS: ₹4.29 (vs ₹2.70 in 1Q 2022) First quarter 2023 results: EPS: ₹4.29 (up from ₹2.70 in 1Q 2022). Revenue: ₹8.21b (up 65% from 1Q 2022). Net income: ₹1.09b (up 59% from 1Q 2022). Profit margin: 13% (in line with 1Q 2022). Upcoming Dividend • Jun 10
Upcoming dividend of ₹1.40 per share Eligible shareholders must have bought the stock before 17 June 2022. Payment date: 27 July 2022. Payout ratio is a comfortable 12% but the company is not cash flow positive. Trailing yield: 1.1%. Lower than top quartile of Indian dividend payers (1.8%). Higher than average of industry peers (0.8%). Reported Earnings • Jun 07
Full year 2022 earnings released: EPS: ₹11.97 (vs ₹7.33 in FY 2021) Full year 2022 results: EPS: ₹11.97 (up from ₹7.33 in FY 2021). Revenue: ₹25.0b (up 53% from FY 2021). Net income: ₹3.04b (up 63% from FY 2021). Profit margin: 12% (in line with FY 2021). Valuation Update With 7 Day Price Move • Jun 01
Investor sentiment improved over the past week After last week's 16% share price gain to ₹133, the stock trades at a trailing P/E ratio of 10.5x. Average trailing P/E is 17x in the Chemicals industry in India. Valuation Update With 7 Day Price Move • May 11
Investor sentiment deteriorated over the past week After last week's 15% share price decline to ₹118, the stock trades at a trailing P/E ratio of 10.4x. Average trailing P/E is 18x in the Chemicals industry in India. Reported Earnings • May 03
Full year 2022 earnings released: EPS: ₹11.97 (vs ₹7.33 in FY 2021) Full year 2022 results: EPS: ₹11.97 (up from ₹7.33 in FY 2021). Revenue: ₹25.9b (up 59% from FY 2021). Net income: ₹3.04b (up 63% from FY 2021). Profit margin: 12% (in line with FY 2021). Board Change • Apr 27
High number of new directors There are 7 new directors who have joined the board in the last 3 years. Independent Director Manubhai Patel was the last director to join the board, commencing their role in 2021. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Recent Insider Transactions • Feb 25
Insider recently bought ₹9.3m worth of stock On the 22nd of February, Jagrutiben Patel bought around 100k shares on-market at roughly ₹93.07 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought ₹59m more in shares than they have sold in the last 12 months. Reported Earnings • Feb 05
Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations Third quarter 2022 results: EPS: ₹2.69 (up from ₹1.42 in 3Q 2021). Revenue: ₹6.40b (up 38% from 3Q 2021). Net income: ₹683.8m (up 90% from 3Q 2021). Profit margin: 11% (up from 7.8% in 3Q 2021). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Recent Insider Transactions • Dec 16
Insider recently bought ₹1.1m worth of stock On the 14th of December, Dhiren Goyal bought around 10k shares on-market at roughly ₹111 per share. In the last 3 months, there was an even bigger purchase from another insider worth ₹9.5m. Insiders have collectively bought ₹48m more in shares than they have sold in the last 12 months. Valuation Update With 7 Day Price Move • Nov 29
Investor sentiment improved over the past week After last week's 17% share price gain to ₹101, the stock trades at a trailing P/E ratio of 11.6x. Average trailing P/E is 17x in the Chemicals industry in India. Recent Insider Transactions • Nov 18
MD & Director recently bought ₹9.5m worth of stock On the 16th of November, Natwarlal Patel bought around 100k shares on-market at roughly ₹95.26 per share. In the last 3 months, there was an even bigger purchase from another insider worth ₹10m. Insiders have collectively bought ₹31m more in shares than they have sold in the last 12 months. Recent Insider Transactions • Nov 18
MD & Director recently bought ₹9.5m worth of stock On the 16th of November, Natwarlal Patel bought around 100k shares on-market at roughly ₹95.26 per share. In the last 3 months, there was an even bigger purchase from another insider worth ₹10m. Insiders have collectively bought ₹31m more in shares than they have sold in the last 12 months. Reported Earnings • Oct 29
Second quarter 2022 earnings released: EPS ₹2.57 (vs ₹1.14 in 2Q 2021) The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2022 results: Revenue: ₹5.48b (up 83% from 2Q 2021). Net income: ₹652.6m (up 125% from 2Q 2021). Profit margin: 12% (up from 9.7% in 2Q 2021). The increase in margin was driven by higher revenue.